MFA Wealth Advisors LLC Purchases 76 Shares of Eli Lilly and Company (NYSE:LLY)

MFA Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 28.6% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 342 shares of the company’s stock after buying an additional 76 shares during the quarter. MFA Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $310,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $32,000. Core Wealth Advisors Inc. raised its stake in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Activest Wealth Management bought a new position in shares of Eli Lilly and Company in the first quarter worth about $39,000. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $29,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on LLY. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price target for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Truist Financial restated a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday. Finally, Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $956.88.

Eli Lilly and Company Trading Up 0.2 %

Shares of Eli Lilly and Company stock traded up $2.00 on Wednesday, reaching $951.97. 2,496,047 shares of the company’s stock were exchanged, compared to its average volume of 3,101,510. The company has a market capitalization of $904.76 billion, a P/E ratio of 140.20, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $967.00. The firm’s 50-day moving average is $883.39 and its two-hundred day moving average is $811.11. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,214,704 shares of company stock worth $1,066,841,316. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.